AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly and Company to research and develop innovative treatments for various cancers.
Under this new agreement, the parties will leverage AdvanCell’s proprietary Pb-212 production technology and radionuclide development infrastructure and Lilly’s drug candidate programs and extensive expertise in drug development to facilitate the development and accelerate the clinical advancement of an expanded portfolio of targeted alpha therapies.
AdvanCell’s competitive advantage in technology development and the infrastructure it has built to accelerate early-stage clinical trials in Australia enables AdvanCell to rapidly develop and progress novel Pb-212-containing radiotherapeutics from discovery into clinical trials.
“This collaboration with Lilly represents a significant milestone for AdvanCell, recognizing our company as one of the leaders in the Pb-212 targeted alpha therapy space,” said Andrew Adamovich, CEO of AdvanCell. “By combining our groundbreaking isotope production capabilities, our team’s expertise and infrastructure with Lilly’s pharmaceutical and oncology expertise and global scale, we aim to bring transformative treatments to patients with hard-to-treat cancers. It is especially pleasing to continue and expand our existing relationship.”
Jacob Van Naarden, President of Lilly Oncology, added, “Partnering with AdvanCell aligns with our commitment to advancing innovative radiopharmaceuticals. We are excited to explore the potential of Pb-212-based alpha therapies as we work to bring meaningful new treatments for patients.”
Financial terms of the agreement were not disclosed.
About AdvanCell
AdvanCell is dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By combining advanced manufacturing capabilities with cutting-edge science and clinical development capabilities, AdvanCell aims to deliver novel treatments that improve outcomes for cancer patients globally. For more information, visit www.advancell.com.au.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210990350/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Announces Normal Course Issuer Bid5.11.2025 23:00:00 CET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) is pleased to announce that the Toronto Stock Exchange (the “TSX”) has accepted a notice (the “Notice”) filed by the Company of its intention to make a normal course issuer bid (the “NCIB”). In connection with the NCIB, the Company has entered into an automatic share purchase plan (an “ASPP”) with its designated broker to allow for purchases of its common shares (the “Shares”). The Notice provides that the Company may, during the 12-month period commencing November 12, 2025 and ending November 11, 2026, or on such earlier date as Kinaxis completes its purchases or provides notice of termination, purchase up to 1,403,042 Shares in total, representing approximately 5% of the issued and outstanding Shares as at October 31, 2025. As of the close of business on October 31, 2025, the Company had 28,060,844 Shares issued and outstanding. Except for block purchases permitted under the rules of the TSX, the number of Shares to be purchased p
Hyper® Wins Dual CES 2026 Innovation Awards® for its Breakthrough Tech Accessories5.11.2025 22:45:00 CET | Press release
Hyper’s HyperSpace™ Trackpad Pro and HyperDrive® Next USB4 M.2 PCIe Enclosure named as CES Innovation Awards® 2026 Honorees Hyper®, a leader in mobile tech accessories for creators and power users, today announced it has been honored with two CES2026 Innovation Awards® in the Consumer Peripherals and Accessories category. These awards reflect Hyper’s mission to build breakthrough solutions that help users create, connect, and go beyond the limits of their devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105297377/en/ CES Innovation Awards® 2026 Honorees: HyperSpace™ Trackpad Pro and HyperDrive® Next redefine haptics, personalization, and next-gen USB4 V2 speed. The CES Innovation Awards program is an annual competition that honors the most innovative, new products in consumer technology, recognizing top innovations across multiple categories. “For 20 years, Hyper has led the tech accessory space with industry-defin
CWAN Reports 800+ AI Agents Now Available for Deployment Across $10 Trillion in Client Assets5.11.2025 22:15:00 CET | Press release
Global institutions deploy CWAN GenAI agents that can scale to millions of daily tasks across reconciliation, reporting, and portfolio management Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced the global deployment of CWAN GenAI, a newly-launched, embedded generative AI platform that can be deployed to transform investment management, risk management, reporting and operations across more than $10 trillion in institutional assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105092732/en/ What sets CWAN GenAI apart from the experimental AI tools flooding the market is its production-ready integration. Unlike copilots or chat tools layered onto legacy systems, CWAN GenAI is fully integrated and deployed into production on CWAN’s front-to-back platform, enabling clients to work alongside AI as collaborative partners in their investment operations. Th
IonQ and Swiss Consortium Launch First Citywide Dedicated Quantum Network in Geneva5.11.2025 22:04:00 CET | Press release
Landmark public-private initiative includes CERN, Rolex SA, Swiss government and academic institutionsDelivers world-class quantum infrastructure to support research, collaboration, and quantum tech awareness IonQ (NYSE: IONQ), the world’s leading quantum company, with luminary Swiss partners, successfully deployed a citywide quantum network in Geneva, Switzerland. This consortium of world-class academic, enterprise, and public institutions will advance quantum cybersecurity and communications research, collaboration, and innovation. The new infrastructure, named the Geneva Quantum Network (GQN), is the nation’s first dedicated quantum network connecting key institutions across the region. “Our involvement in the GQN alongside globally-renowned companies such as Rolex and research leaders like CERN, underscores our IP and pioneering leadership in quantum cybersecurity and communication,” said Niccolo de Masi, Chairman and CEO of IonQ. “IonQ is leveraging existing fiber optic infrastruc
PPG sets paint stirring world record at SEMA 2025 to highlight benefits of new automated system for body shops5.11.2025 19:41:00 CET | Press release
SEMMIX’N’SHAKE system cuts time, waste in refinish industry PPG (NYSE: PPG) today announced that it achieved a GUINNESS WORLD RECORDS™ title for the largest simultaneous paint stirring challenge during a customer event at the 2025 SEMA Show in Las Vegas. More than 275 participants stirred paint together to highlight the manual effort still common in collision repair before PPG unveiled its new SEM MIX’N’SHAKE™ automated stirring solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105923792/en/ More than 275 participants simultaneously stirred paint at SEMA 2025 as PPG breaks the GUINNESS WORLD RECORDS™ title for the largest paint stirring challenge as it unveiled the SEM Mix’n’Shake™ automated stirring system. The SEM Mix’n’Shake system produces a fully homogenized car paint mix in less than 60 seconds. By automating this step, body shops can reduce rework and recover up to 6% more productive work hours annually. The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom